Your browser doesn't support javascript.
loading
The Diagnostic Value of PSMA PET-CT in Differentiating Medication-Related Osteonecrosis of the Jaw and Metastasis to the Jawbone.
Kur, Karin; Papadopoulou, Erofili; Nidam, Meital; Fertouk, Michal; Binyamini, Omer; Friedlander Barenboim, Silvina; Lazarovitci, Towy Sorel; Domachevsky, Liran; Yarom, Noam.
Afiliación
  • Kur K; Oral Medicine Unit, Sheba Medical Center, Tel-Hashomer, Israel.
  • Papadopoulou E; Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, Greece.
  • Nidam M; Nuclear Medicine Institute, Sheba Medical Center, Tel-Hashomer, Israel.
  • Fertouk M; Nuclear Medicine Institute, Sheba Medical Center, Tel-Hashomer, Israel.
  • Binyamini O; In partial fulfillment of DMD degree, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Friedlander Barenboim S; Oral Medicine Unit, Sheba Medical Center, Tel-Hashomer, Israel.
  • Lazarovitci TS; Department of Oro-maxillofacial Surgery, Sheba Medical Center, Tel-Hashomer, Israel.
  • Domachevsky L; Nuclear Medicine Institute, Sheba Medical Center, Tel-Hashomer, Israel.
  • Yarom N; Faculty of Health and Medical Sciences, Tel Aviv University, Tel Aviv, Israel.
Dentomaxillofac Radiol ; 2024 Aug 01.
Article en En | MEDLINE | ID: mdl-39087565
ABSTRACT

INTRODUCTION:

Medication-related osteonecrosis of the jaw (MRONJ) and jaw metastasis might share similar clinical and radiographic characteristics, with both demonstrating FDG uptake on PET-CT. Prostate-specific membrane antigen (PSMA) PET-CT is used to demonstrate prostate cancer dissemination. Unlike FDG PET-CT, PSMA PET-CT is more specific to cancer than to inflammation. Therefore, we hypothesized that it might be a useful tool to differentiate between MRONJ and jaw metastasis. MATERIALS AND

METHODS:

All files of prostate cancer patients diagnosed with MRONJ and with available PSMA PET-CT studies were retrieved. A similar number of solid cancer patients with MRONJ and with available FDG PET-CT studies served as a second study group. All studies were reviewed by two blinded co-investigators (LD, MF).

RESULTS:

Seventeen patients who underwent PSMA PET-CT (24 studies) and 15 patients who underwent FDG PET-CT (29 studies) met the inclusion criteria. All patients with FDG PET-CT studies showed pathological uptake at the site of MRONJ in at least one of their studies versus only 23.5% of patients in the PSMA PET-CT group (P < 0.001). FDG PET-CT studies showed pathological uptake in 89.6% of the studies compared to only 20.8% in the PSMA PET-CT group (P < 0.001). The mean standardized uptake value (SUVmax) and the mean uptake volume in the FDG PET-CT group were significantly higher compared to the PSMA PET-CT group (P < 0.001 and P < 0.005, respectively). The interclass correlation coefficient for all parameters was higher than 0.95.

CONCLUSIONS:

PSMA PET-CT is useful to differentiate between MRONJ and jaw metastasis.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dentomaxillofac Radiol Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dentomaxillofac Radiol Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Reino Unido